Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial

Emre M., Tsolaki M., Bonuccelli U., Destee A., Tolosa E., Kutzelnigg A., ...More

LANCET NEUROLOGY, vol.9, no.10, pp.969-977, 2010 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 9 Issue: 10
  • Publication Date: 2010
  • Doi Number: 10.1016/s1474-4422(10)70194-0
  • Journal Name: LANCET NEUROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.969-977
  • Istanbul University Affiliated: Yes

Abstract

Background Previous studies have suggested that patients with Lewy-body-related dementias might benefit from treatment with the N-methyl D-aspartate receptor antagonist memantine, but further data are needed. Therefore, the efficacy and safety of memantine were investigated in patients with mild to moderate Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB).